within Pharmacolibrary.Drugs.ATC.D;

model D10BA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.33999999999999997,
    adminDuration  = 600,
    adminMass      = 0.04,
    adminCount     = 1,
    Vd             = 0.166,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009666666666666665,
    Tlag           = 498.00000000000006
  );

  annotation(Documentation(
    info ="<html><body><p>Isotretinoin is a retinoid derivative (13-cis-retinoic acid) used primarily in the treatment of severe recalcitrant nodular acne. It is also occasionally used for other keratinization disorders. Isotretinoin is an oral drug approved by regulatory authorities such as the FDA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers under fasting conditions (single oral dose administration).</p><h4>References</h4><ol><li><p>Wiegand, UW, &amp; Chou, RC (1998). Pharmacokinetics of oral isotretinoin. <i>Journal of the American Academy of Dermatology</i> 39(2 Pt 3) S8–S12. DOI:<a href=&quot;https://doi.org/10.1016/s0190-9622(98)70438-4&quot;>10.1016/s0190-9622(98)70438-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9703117/&quot;>https://pubmed.ncbi.nlm.nih.gov/9703117</a></p></li><li><p>Jones, M, Armstrong, AW, Baldwin, H, Stein Gold, L, &amp; Kircik, LH (2021). ARTICLE: Advances in Oral Isotretinoin Therapy. <i>Journal of drugs in dermatology : JDD</i> 20(5) s5–s11. DOI:<a href=&quot;https://doi.org/10.36849/JDD.s072A&quot;>10.36849/JDD.s072A</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33938693/&quot;>https://pubmed.ncbi.nlm.nih.gov/33938693</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D10BA01;
